



Antiemetic Dosage Recommendations for Children receiving <u>HIGHLY</u> Emetogenic Antineoplastic Therapy	
Drug	Dose
<b>Aprepitant</b>	Day 1: 125 mg PO x 1 Days 2 and 3: 80mg PO once daily <i>*Note: The risks and benefits of using aprepitant should be discussed with patients' tertiary centres with particular consideration of potential drug interactions</i>
<b>Dexamethasone</b>	6 mg/m <sup>2</sup> /dose IV/PO q6h If given concurrently with aprepitant, reduce dexamethasone dose by half.
<b>Granisetron</b>	40 mcg/kg/dose IV as a single daily dose
<b>Ondansetron</b>	5 mg/m <sup>2</sup> /dose (0.15 mg/kg/dose) IV/PO pre-therapy x 1 and then q8h
<b>Chlorpromazine</b>	0.5mg/kg/dose IV q6h
<b>Nabilone</b>	< 18 kg: 0.5 mg/dose PO twice daily 18 to 30 kg: 1 mg/dose PO twice daily > 30 kg: 1 mg/dose PO three times daily Maximum: 0.06 mg/kg/day



Antiemetic Dosage Recommendations for Children receiving <b>MODERATELY</b> Emetogenic Antineoplastic Therapy	
Drug	Dose
<b>Dexamethasone</b>	≤ <b>0.6m<sup>2</sup></b> : 2mg/dose IV/PO q12h > <b>0.6m<sup>2</sup></b> : 4mg/dose IV/PO q12h
<b>Granisetron</b>	40 mcg/kg/dose IV as a single daily dose <u>or</u> 40 mcg/kg/dose PO q12h
<b>Ondansetron</b>	5 mg/m <sup>2</sup> /dose (0.15 mg/kg/dose) IV/PO pre-therapy x 1 and then q8h
<b>Chlorpromazine</b>	0.5mg/kg/dose IV q6h
<b>Metoclopramide</b>	1 mg/kg/dose IV pre-therapy x 1 then 0.0375 mg/kg/dose PO q6h Give diphenhydramine or benztropine concurrently.
<b>Nabilone</b>	< 18 kg: 0.5 mg/dose PO twice daily 18 to 30 kg: 1 mg/dose PO twice daily > 30 kg: 1 mg/dose PO three times daily <u>Maximum</u> : 0.06 mg/kg/day

Low  
emetogenic  
risk

ondansetron **or**  
granisetron

Antiemetic Dosage Recommendations for Children receiving <u>LOW</u> Emetogenic Antineoplastic Therapy	
Drug	Dose
<b>Granisetron</b>	40 mcg/kg/dose IV as a single daily dose <u>or</u> 40 mcg/kg/dose PO q12h
<b>Ondansetron</b>	5 mg/m <sup>2</sup> /dose (0.15 mg/kg/dose) IV/PO pre-therapy x 1 and then q8h

Minimal  
emetogenic  
risk

no routine  
prophylaxis